Pharmafile Logo
Pharmafocus logo
Advanced Search

Welcome to the real world

pharmafile | August 21, 2008 | Feature | Research and Development |  clinical trials, design, observational, phase III 

Related Content

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.

By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, …

EMA selects TrialAssure anonymisation platform for clinical trial documents

TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …

The Gateway to Local Adoption Series

Latest content

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

October 4, 2026

Brenntag and dsm-firmenich expand biopharma vitamin partnership

October 4, 2026

CeramTec expands German production capacity for orthopaedic ceramics

October 2, 2026

Migraine annual economic and quality-of-life burden in UK

October 1, 2026

bit.bio expands human heart cell portfolio through myriamed partnership

September 30, 2026